# US 2020/0392136 A1 · Inhibiting the transient receptor potential a1 ion channel

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392136 A1
- Document ID: US20200392136A1
- Status: Published application
- Kind: A1
- Application number: 16/763,125
- Filed: 2019-01-30
- Published: 2020-12-17
- Earliest claimed: 2018-01-31
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: Xinyuan Edward WU
- Web page: https://patentgrep.com/patent/US20200392136A1

## CPC

- C07D 473/06: with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D 487/04: Ortho-condensed systems
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61P 23/00: Anaesthetics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).

## Claims

### Claim at position 1

1-67. (canceled)

### Claim 68

A compound of the formula:
wherein the compound is of greater than 95% purity,
or a pharmaceutically acceptable salt thereof.

### Claim 69

A compound of the formula:
wherein the compound is of greater than 95% purity.

### Claim 70

A pharmaceutical composition, comprising a compound of the formula:
or a pharmaceutically acceptable salt thereof, in a mixture with a pharmaceutically acceptable excipient, diluent, or carrier.

### Claim 71

A pharmaceutical composition comprising a compound of the formula:
in a mixture with a pharmaceutically acceptable excipient, diluent, or carrier.

### Claim 72 (depends on 70)

The pharmaceutical composition according to claim 70 wherein the composition is for oral administration.

### Claim 73

A method of treating pain in a subject, comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 74 (depends on 73)

The method of treating pain in a subject according to claim 73 wherein the compound is:

### Claim 75

A pharmaceutical composition, comprising a compound of the formula:
or a pharmaceutically acceptable salt thereof, in a mixture with a pharmaceutically acceptable excipient, diluent, or carrier.

### Claim 76

A method of treating pain in a subject, comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 77 (depends on 76)

The method of treating pain in a subject according to claim 76 wherein the compound is:

### Claim 78 (depends on 73)

The method of claim 73 wherein the pain is chronic pain.

### Claim 79 (depends on 74)

The method of claim 74 wherein the pain is chronic pain.

### Claim 80 (depends on 76)

The method of claim 76 wherein the pain is chronic pain.

### Claim 81 (depends on 77)

The method of claim 77 wherein the pain is chronic pain.